1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: In Vivo Cell Reprogramming Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. In Vivo Cell Reprogramming Market, by January
8.1.1. Therapeutics / Reprogramming Agents
8.1.1.1. Market Revenue and Forecast
8.1.2. Delivery Systems / Devices
8.1.2.1. Market Revenue and Forecast
8.1.3. Supportive Tools & Diagnostics
8.1.3.1. Market Revenue and Forecast
9.1. In Vivo Cell Reprogramming Market, by Reprogramming Approach / Technology
9.1.1. Direct lineage reprogramming / transdifferentiation (e.g., fibroblast → cardiomyocyte)
9.1.1.1. Market Revenue and Forecast
9.1.2. In vivo partial reprogramming (transient expression of Yamanaka factors to restore function/ageing reversal)
9.1.2.1. Market Revenue and Forecast
9.1.3. In vivo transgene replacement + reprogramming (gene replacement combined with cell identity shift)
9.1.3.1. Market Revenue and Forecast
9.1.4. Cell fate conversion via epigenetic remodeling (small molecules / epigenetic drugs)
9.1.4.1. Market Revenue and Forecast
9.1.5. In vivo delivery of mRNA / protein TFs (transient reprogramming)
9.1.5.1. Market Revenue and Forecast
9.1.5. Genome editing–mediated reprogramming (knock-in/out regulatory nodes to enforce new cell fate)
9.1.5.1. Market Revenue and Forecast
10.1. In Vivo Cell Reprogramming Market, by Cell / Source Type
10.1.1. Fibroblasts
10.1.1.1. Market Revenue and Forecast
10.1.2. Endothelial cells / vascular cells
10.1.2.1. Market Revenue and Forecast
10.1.3. Epithelial cells (skin, lung epithelium)
10.1.3.1. Market Revenue and Forecast
10.1.4. Glial cells/astrocyte
10.1.4.1. Market Revenue and Forecast
10.1.5. Cardiac fibroblasts/cardiomyocytes
10.1.5.1. Market Revenue and Forecast
10.1.5. Pancreatic exocrine cells/alpha cells → beta cells
10.1.5.1. Market Revenue and Forecast
10.1.5. Hepatocytes / hepatic stellate cells
10.1.5.1. Market Revenue and Forecast
10.1.5. Skeletal muscle cells
10.1.5.1. Market Revenue and Forecast
11.1. In Vivo Cell Reprogramming Market, by Target Tissue / Organ
11.1.1. Cardiac (heart repair/cardiomyocyte generation)
11.1.1.1. Market Revenue and Forecast
11.1.2. Neurological (brain, spinal cord — neuron regeneration)
11.1.2.1. Market Revenue and Forecast
11.1.3. Pancreas (β-cell regeneration for diabetes)
11.1.3.1. Market Revenue and Forecast
11.1.4. Liver (hepatocyte regeneration/fibrosis reversal)
11.1.4.1. Market Revenue and Forecast
11.1.5. Lung (alveolar epithelial repair)
11.1.5.1. Market Revenue and Forecast
11.1.6. Skin & wound healing
11.1.6.1. Market Revenue and Forecast
11.1.7. Retina & ocular tissues
11.1.7.1. Market Revenue and Forecast
11.1.8. Musculoskeletal (skeletal muscle, cartilage)
11.1.8.1. Market Revenue and Forecast
12.1. In Vivo Cell Reprogramming Market, by Indication / Disease Area
12.1.1. Cardiovascular diseases (MI, heart failure)
12.1.1.1. Market Revenue and Forecast
12.1.2. Neurological disorders (Parkinson’s, spinal cord injury, stroke)
12.1.2.1. Market Revenue and Forecast
12.1.3. Metabolic disease (Type 1 diabetes)
12.1.3.1. Market Revenue and Forecast
12.1.4. Liver disease & fibrosis
12.1.4.1. Market Revenue and Forecast
12.1.5. Ophthalmic diseases (retinal dystrophies)
12.1.5.1. Market Revenue and Forecast
12.1.6. Wound healing & dermatology
12.1.6.1. Market Revenue and Forecast
12.1.7. Musculoskeletal disorders (OA, muscle loss)
12.1.7.1. Market Revenue and Forecast
12.1.8. Oncology (reprogramming tumor microenvironment / immune reprogramming)
12.1.8.1. Market Revenue and Forecast
13.1. In Vivo Cell Reprogramming Market, by End-User
13.1.1. Hospitals & specialty clinics (cardiac centers, neurocenters)
13.1.1.1. Market Revenue and Forecast
13.1.2. Biotech & pharmaceutical companies (product development)
13.1.2.1. Market Revenue and Forecast
13.1.3. Academic & research institutes (R&D)
13.1.3.1. Market Revenue and Forecast
13.1.4. Contract development & manufacturing organizations (CDMOs) for vectors/biologics
13.1.4.1. Market Revenue and Forecast
13.1.5. Diagnostics & companion diagnostics providers
13.1.5.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by January
14.1.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.1.3. Market Revenue and Forecast, by Cell / Source Type
14.1.4. Market Revenue and Forecast, by Target Tissue / Organ
14.1.5. Market Revenue and Forecast, by Indication / Disease Area
14.1.6. Market Revenue and Forecast, by End-User
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by January
14.1.7.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.1.7.3. Market Revenue and Forecast, by Cell / Source Type
14.1.7.4. Market Revenue and Forecast, by Target Tissue / Organ
14.1.8. Market Revenue and Forecast, by Indication / Disease Area
14.1.8.1. Market Revenue and Forecast, by End-User
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by January
14.1.9.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.1.9.3. Market Revenue and Forecast, by Cell / Source Type
14.1.9.4. Market Revenue and Forecast, by Target Tissue / Organ
14.1.10. Market Revenue and Forecast, by Indication / Disease Area
14.1.11. Market Revenue and Forecast, by End-User
14.2. Europe
14.2.1. Market Revenue and Forecast, by January
14.2.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.2.3. Market Revenue and Forecast, by Cell / Source Type
14.2.4. Market Revenue and Forecast, by Target Tissue / Organ
14.2.5. Market Revenue and Forecast, by Indication / Disease Area
14.2.6. Market Revenue and Forecast, by End-User
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by January
14.2.8.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.2.8.3. Market Revenue and Forecast, by Cell / Source Type
14.2.9. Market Revenue and Forecast, by Target Tissue / Organ
14.2.10. Market Revenue and Forecast, by Indication / Disease Area
14.2.10.1. Market Revenue and Forecast, by End-User
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by January
14.2.11.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.2.11.3. Market Revenue and Forecast, by Cell / Source Type
14.2.12. Market Revenue and Forecast, by Target Tissue / Organ
14.2.13. Market Revenue and Forecast, by Indication / Disease Area
14.2.14. Market Revenue and Forecast, by End-User
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by January
14.2.15.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.2.15.3. Market Revenue and Forecast, by Cell / Source Type
14.2.15.4. Market Revenue and Forecast, by Target Tissue / Organ
14.2.16. Market Revenue and Forecast, by Indication / Disease Area
14.2.16.1. Market Revenue and Forecast, by End-User
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by January
14.2.17.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.2.17.3. Market Revenue and Forecast, by Cell / Source Type
14.2.17.4. Market Revenue and Forecast, by Target Tissue / Organ
14.2.18. Market Revenue and Forecast, by Indication / Disease Area
14.2.18.1. Market Revenue and Forecast, by End-User
14.3. APAC
14.3.1. Market Revenue and Forecast, by January
14.3.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.3.3. Market Revenue and Forecast, by Cell / Source Type
14.3.4. Market Revenue and Forecast, by Target Tissue / Organ
14.3.5. Market Revenue and Forecast, by Indication / Disease Area
14.3.6. Market Revenue and Forecast, by End-User
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by January
14.3.7.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.3.7.3. Market Revenue and Forecast, by Cell / Source Type
14.3.7.4. Market Revenue and Forecast, by Target Tissue / Organ
14.3.8. Market Revenue and Forecast, by Indication / Disease Area
14.3.9. Market Revenue and Forecast, by End-User
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by January
14.3.10.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.3.10.3. Market Revenue and Forecast, by Cell / Source Type
14.3.10.4. Market Revenue and Forecast, by Target Tissue / Organ
14.3.11. Market Revenue and Forecast, by Indication / Disease Area
14.3.11.1. Market Revenue and Forecast, by End-User
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by January
14.3.12.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.3.12.3. Market Revenue and Forecast, by Cell / Source Type
14.3.12.4. Market Revenue and Forecast, by Target Tissue / Organ
14.3.12.5. Market Revenue and Forecast, by Indication / Disease Area
14.3.12.6. Market Revenue and Forecast, by End-User
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by January
14.3.13.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.3.13.3. Market Revenue and Forecast, by Cell / Source Type
14.3.13.4. Market Revenue and Forecast, by Target Tissue / Organ
14.3.13.5. Market Revenue and Forecast, by Indication / Disease Area
14.3.13.6. Market Revenue and Forecast, by End-User
14.4. MEA
14.4.1. Market Revenue and Forecast, by January
14.4.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.4.3. Market Revenue and Forecast, by Cell / Source Type
14.4.4. Market Revenue and Forecast, by Target Tissue / Organ
14.4.5. Market Revenue and Forecast, by Indication / Disease Area
14.4.6. Market Revenue and Forecast, by End-User
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by January
14.4.7.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.4.7.3. Market Revenue and Forecast, by Cell / Source Type
14.4.7.4. Market Revenue and Forecast, by Target Tissue / Organ
14.4.8. Market Revenue and Forecast, by Indication / Disease Area
14.4.9. Market Revenue and Forecast, by End-User
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by January
14.4.10.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.4.10.3. Market Revenue and Forecast, by Cell / Source Type
14.4.10.4. Market Revenue and Forecast, by Target Tissue / Organ
14.4.11. Market Revenue and Forecast, by Indication / Disease Area
14.4.12. Market Revenue and Forecast, by End-User
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by January
14.4.13.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.4.13.3. Market Revenue and Forecast, by Cell / Source Type
14.4.13.4. Market Revenue and Forecast, by Target Tissue / Organ
14.4.13.5. Market Revenue and Forecast, by Indication / Disease Area
14.4.13.6. Market Revenue and Forecast, by End-User
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by January
14.4.14.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.4.14.3. Market Revenue and Forecast, by Cell / Source Type
14.4.14.4. Market Revenue and Forecast, by Target Tissue / Organ
14.4.14.5. Market Revenue and Forecast, by Indication / Disease Area
14.4.14.6. Market Revenue and Forecast, by End-User
14.5. Latin America
14.5.1. Market Revenue and Forecast, by January
14.5.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.5.3. Market Revenue and Forecast, by Cell / Source Type
14.5.4. Market Revenue and Forecast, by Target Tissue / Organ
14.5.5. Market Revenue and Forecast, by Indication / Disease Area
14.5.6. Market Revenue and Forecast, by End-User
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by January
14.5.7.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.5.7.3. Market Revenue and Forecast, by Cell / Source Type
14.5.7.4. Market Revenue and Forecast, by Target Tissue / Organ
14.5.8. Market Revenue and Forecast, by Indication / Disease Area
14.5.8.1. Market Revenue and Forecast, by End-User
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by January
14.5.9.2. Market Revenue and Forecast, by Reprogramming Approach / Technology
14.5.9.3. Market Revenue and Forecast, by Cell / Source Type
14.5.9.4. Market Revenue and Forecast, by Target Tissue / Organ
14.5.9.5. Market Revenue and Forecast, by Indication / Disease Area
14.5.9.6. Market Revenue and Forecast, by End-User
15.1. Sangamo Therapeutics
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. LyGenesis
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Rejuvenate Bio
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. uniQure
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Voyager Therapeutics
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. BlueRock Therapeutics
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Spark Therapeutics
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Abbott
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Abbott
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Abbott
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
